Bio-Techne Corporation, a leading bio-tech company, has had a series of notable activities and achievements, represented in the mentioned news reports. The company announced a
strategic investment in Spear Bio alongside new distribution deals and partnerships, strengthening its market position in
cell and gene therapy manufacturing. Substantial noted milestones include surpassing 10,000
peer-reviewed publications citing its RNA scope technology, the launch of next-generation high throughput Western Systems, and the receipt of IVDR certification for a chronic myeloid leukemia diagnostic test. They also showcased their innovative MauriceFlex™ system at a well-known conference. A frequent investor sentiment towards Bio-Techne's stock is a '
Moderate Buy', despite some headwinds faced in Q1, including a dip in revenue per share. However, a recent
stock split promises potential gains for investors. The appointment of Matthew F. McManus as President of Diagnostics and Genomics Segment, along with Kim Kelderman as CEO, are signs of significant
leadership transition within the company. Bio-Techne also completed the acquisition of Lunaphore, thus boosting its offerings in spatial biology.
Bio-Techne Corp TECH News Analytics from Wed, 03 Mar 2021 08:00:00 GMT to Sun, 25 Aug 2024 13:00:23 GMT -
Rating 7
- Innovation 8
- Information 9
- Rumor -5
